StreetInsider.com News Articles

HEALWELL to Deploy AI-Powered SMART Search and SMART Summary Across Statewide U.S. Health Information Exchange

Tue, 01 Sep 2026 06:00:00 -0400

HEALWELL, through its subsidiary Orion Health, has entered into an agreement with the statewide designated Health Information Exchange of Iowa, Converge Health Iowa, to deploy DARWEN™-powered SMART Search and SMART Summary.
The agreement represents a multi-million-dollar, multi-year enterprise opportunity, and is expected to generate recurring revenue over its term that is substantial relative to the current run rate of HEALWELL's AI & Data Sciences business unit.
SMART Search and SMART Summary are designed to reduce clinical burden on physicians at the point of care, extracting relevant clinical facts from complex, longitudinal patient records with document-level traceable provenance. This allows

HEALWELL to Deploy AI-Powered SMART Search and SMART Summary Across Statewide U.S. Health Information Exchange

Tue, 01 Sep 2026 06:00:00 -0400

HEALWELL, through its subsidiary Orion Health, has entered into an agreement with the statewide designated Health Information Exchange of Iowa, Converge Health Iowa, to deploy DARWEN™-powered SMART Search and SMART Summary.
The agreement represents a multi-million-dollar, multi-year enterprise opportunity, and is expected to generate recurring revenue over its term that is substantial relative to the current run rate of HEALWELL's AI & Data Sciences business unit.
SMART Search and SMART Summary are designed to reduce clinical burden on physicians at the point of care, extracting relevant clinical facts from complex, longitudinal patient records with document-level traceable provenance. This allows

20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

Fri, 28 Aug 2026 18:26:00 -0400

CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption

Webinar to Be Held Wednesday, September 2, 2026 at 2:00 p.m. Eastern Time; Registration Is Now Open

GAITHERSBURG, Md., Aug. 28, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced

20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

Fri, 28 Aug 2026 18:26:00 -0400

Webinar to Be Held Wednesday, September 2, 2026 at 2:00 p.m. Eastern Time; Registration Is Now Open

20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

Fri, 28 Aug 2026 18:26:00 -0400

Webinar to Be Held Wednesday, September 2, 2026 at 2:00 p.m. Eastern Time; Registration Is Now Open

20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

Fri, 28 Aug 2026 18:26:00 -0400

Webinar to Be Held Wednesday, September 2, 2026 at 2:00 p.m. Eastern Time; Registration Is Now Open

20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

Wed, 26 Aug 2026 08:31:00 -0400

Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open

GAITHERSBURG, Md., Aug. 26, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that

20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

Wed, 26 Aug 2026 08:31:00 -0400

Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open

20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

Wed, 26 Aug 2026 08:31:00 -0400

Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open

20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

Wed, 26 Aug 2026 08:31:00 -0400

Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open

Form DEFA14A 20/20 Biolabs, Inc.

Wed, 19 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260819/26950845.html

Form DEFA14A 20/20 Biolabs, Inc.

Wed, 19 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260819/26950845.html

Form 8-K 20/20 Biolabs, Inc. For: Aug 18

Wed, 19 Aug 2026 09:19:00 -0400

si-local-file:///var/storage/secattach/20260819/26948126.html

Form 8-K 20/20 Biolabs, Inc. For: Aug 18

Wed, 19 Aug 2026 09:19:00 -0400

si-local-file:///var/storage/secattach/20260819/26948126.html

Form 424B3 20/20 Biolabs, Inc.

Mon, 17 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260817/26938092.html

Form 424B3 20/20 Biolabs, Inc.

Mon, 17 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260817/26938092.html

Form 424B3 20/20 Biolabs, Inc.

Mon, 17 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260817/26938043.html

Form 424B3 20/20 Biolabs, Inc.

Mon, 17 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260817/26938043.html

Form 8-K 20/20 Biolabs, Inc. For: Aug 17

Mon, 17 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260817/26937963.html

Form 8-K 20/20 Biolabs, Inc. For: Aug 17

Mon, 17 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260817/26937963.html

20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

Mon, 17 Aug 2026 08:31:00 -0400

Best Quarter of Flagship Multi-Cancer Early Detection Testing; OneTest™ Revenue Increased 47% Year-Over-Year to $0.7 Million; Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding to 41.7% from 30.5%

Company Expands OneTest™ Across Firefighter, Occupational Health, Military, and Physician Practice Markets

Cash Position Strengthened to $4.5 Million as of June 30, 2026, with All Convertible Note Debt Eliminated During the Quarter

GAITHERSBURG, Md., Aug. 17, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for

20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

Mon, 17 Aug 2026 08:31:00 -0400

Company Expands OneTest™ Across Firefighter, Occupational Health, Military, and Physician Practice Markets

Cash Position Strengthened to $4.5 Million as of June 30, 2026, with All Convertible Note Debt Eliminated During the Quarter

GAITHERSBURG, Md., Aug. 17, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for

20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

Mon, 17 Aug 2026 08:31:00 -0400

Company Expands OneTest™ Across Firefighter, Occupational Health, Military, and Physician Practice Markets

Cash Position Strengthened to $4.5 Million as of June 30, 2026, with All Convertible Note Debt Eliminated During the Quarter

GAITHERSBURG, Md., Aug. 17, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for

20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

Mon, 17 Aug 2026 08:31:00 -0400

Company Expands OneTest™ Across Firefighter, Occupational Health, Military, and Physician Practice Markets

Cash Position Strengthened to $4.5 Million as of June 30, 2026, with All Convertible Note Debt Eliminated During the Quarter

GAITHERSBURG, Md., Aug. 17, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for

Form 10-Q 20/20 Biolabs, Inc. For: Jun 30

Fri, 14 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260814/26930446.html